Expanding MRD testing to more patients with colorectal cancer
Giving clinicians Latitude™ when ordering MRD testing
Latitude™ is a tissue-free, blood-based, residual disease test (MRD) that delivers fast and reliable results without the need for tumor tissue. Latitude™ is built using a targeted panel, composed of differentially methylated regions specifically for colorectal cancer (CRC). Latitude™ offers strong performance, with high sensitivity and specificity for detecting residual disease in CRC patients.
Latitude™ status post-operatively is highly prognostic
The Clinical performance in a 195 patient, 1300+ samples CRC study using samples from the CIRCULATE-JAPAN GALAXY Study
- Patients who tested negative with Latitude™ had significantly longer DFS compared to those who tested positive. HR ratio of 10, p<0.001
- 58% MRD time point sensitivity
- 81% longitudinal sensitivity (84% colon only)
- 97% Sample Level Specificity
- 4.6 months lead time before radiographic relapse
Determine which patients will benefit from ACT
- Patients who were Latitude™-negative derived little benefit from adjuvant chemotherapy (ACT), whereas Latitude™-positive patients experienced a clinical benefit from ACT
- Latitude™ positive patients who did not receive ACT went on to relapse representing a PPV of 100% (26/26)
How to order Latitude™
